Distribution of contemporary sensitivity troponin in the emergency department and relationship to 30-day mortality: The CHARIOT-ED substudy

The Relationship Between Cardiac Troponin in People Hospitalised for Exacerbation of COPD and Major Adverse Cardiac Events (MACE) and COPD Readmissions

“…11 Similarly, hsTrop levels were associated with outcomes in emergency room and intensive care patients. 23,24 These previous findings are consistent with our study and indicate that there is potential clinical value in using hsTrop levels to predict outcome in patients admitted with exacerbation of COPD. However, such risk stratification would be of much greater value if future research could yield a pathway in which detection of elevated troponin then led to precise diagnosis and intervention that altered the subsequent event rate.…”

Is high sensitivity troponin, taken regardless of a clinical indication, associated with 1 year mortality in critical care patients?

“…6,[10][11][12][13]20 This group has previously demonstrated a link between hs-cTnI concentration and short term mortality in patients in the emergency department and those on critical care, even those in whom there was no traditional indication to measure the assay. 2,15 Furthermore, in the CHARIOT study, we previously demonstrated that hs-cTnI was independently associated with 1 year mortality in a consecutive cohort of 20,000 patients undergoing a blood test for any reason at the hospital. 14 The current results are consistent with a previous study, which enrolled 1124 (89%) of patients presenting to CC with sepsis, and found that hs-cTnI concentrations were independently associated with 14 day outcome but not after this timeframe, regardless of whether there was any clinical indication for performing the test.…”

“…6,10–13,20 This group has previously demonstrated a link between hs-cTnI concentration and short term mortality in patients in the emergency department and those on critical care, even those in whom there was no traditional indication to measure the assay. 2,15 Furthermore, in the CHARIOT study, we previously demonstrated that hs-cTnI was independently associated with 1 year mortality in a consecutive cohort of 20,000 patients undergoing a blood test for any reason at the hospital. 14…”

“…The increased sensitivity and usage of high sensitivity troponin (hs-cTn) assays has resulted in concentrations above the manufacturer defined upper limit of normal (ULN) being seen in a range of different clinical contexts not traditionally associated with myocardial infarction. 1–5 Furthermore, there is an accumulating body of evidence demonstrating that hs-cTn is associated with medium term outcomes in several disease groups. 6–14 Specifically, this research group showed that in a population of 20,000 consecutive patients undergoing a blood test for any reason, inpatient or outpatient, the hs-cTnI concentration was above the ULN in 1 in 20.…”

Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y12 Receptor Antagonists

“…Despite the widespread introduction of percutaneous coronary intervention (PCI) into clinical practice, the mortality rate in patients with ST-segment elevation myocardial infarction (STEMI) remains high and averages 5–7%. 1) 2) 3) 4) This state of affairs is due to the fact that drugs used to treat acute myocardial infarction (AMI) do not have a significant effect on the mortality rate in patients with AMI. 5) 6) Investigators have been developing pharmacological agents that can increase cardiac tolerance to ischemia/reperfusion (I/R) for about 50 years.…”